Cover Image
市場調查報告書

自動放射性合成模組的全球市場:趨勢與分析

Automated Radiosynthesis Modules Market - Global Opportunity Analysis and Industry Forecast, 2014-2022

出版商 Allied Market Research 商品編碼 486144
出版日期 內容資訊 英文 36 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
自動放射性合成模組的全球市場:趨勢與分析 Automated Radiosynthesis Modules Market - Global Opportunity Analysis and Industry Forecast, 2014-2022
出版日期: 2016年11月30日 內容資訊: 英文 36 Pages
簡介

本報告提供自動放射性合成模組的全球市場相關分析,提供市場成長的主要影響因素,金額/數量·各地區的詳細市場趨勢,市場發展的方向性,競爭情形,並彙整主要企業的簡介等資訊。

第1章 調查手法

第2章 市場概要

  • 市場範圍·定義
  • 市場動態
    • 成長推動因素
    • 成長阻礙因素
    • 市場課題
  • 波特的五力分析
  • 市場佔有率分析

第3章 自動放射性合成模組的全球市場:金額·不同產量

  • 市場規模與預測

第4章 自動放射性合成模組的全球市場:各地區

  • 北美
  • 亞太地區
  • 歐洲
  • 南美·中東·非洲

第5章 企業簡介

  • GE Healthcare
  • Siemens Healthcare
  • IBA Radiopharma Solutions
  • Optimized Radiochemical Applications
  • Synthra GmbH
  • Eckert
  • Ziegler Group
目錄
Product Code: LI 161761

Automated Radiosynthesis Module Market Overview

Global Automated Radiosynthesis Module Market was valued at $20 million in 2015, and is expected to reach $32 million by 2022, supported by a CAGR of 6.6%. Radiosynthesis modules are available as automated equipment for decentralized settings for the formulation and production of radiotracers. Majority of the radiotracers are manufactured in the centralized laboratories and radiopharmaceutical units. This scenario has few imitations such as it reduces the scope for customization of production of radiotracer and increases the time gap for the radiotracer to reach the end users. As radiotracers have limited half-life, its performance decreases when employed for diagnosis or therapy administration. Automated radiosynthesis modules are simple to set up and easy to use and offers the scope for customization of the radiotracers. This in turn drives the performance of the diagnostic and therapy monitoring activities for the end users.

Rise in incidence of chronic diseases and increase in adoption of PET/SPECT imaging fuel the automation of radiotracer production process. Further, the supply of these products is anticipated to become streamlined and effective, owing to the improved cGMP guideline from the FDA. Manufacturers are expected to gain additional income by diversifying their product offering to cater to the needs of new markets. Premium pricing is projected to remain a source of concern and limit the rate of adoption of these module; however, the availability of funds and grants from the government is expected to offset this constraint.

image1

image2

The above figure indicates that the option for radiotherapy for cancer treatment is available worldwide depicting high radiopharmaceuticals adoption. Thus, along with the growth in radiopharmaceuticals market, the automated radiosynthesis module is anticipated to witness a parallel growth, since it is the technique used to produce radiopharmaceuticals. Hence, the increased incidence of cancer cases worldwide is expected to propel the growth of the automated radiosynthesis module market.

image3

INCREASE IN ADOPTION OF PET & SPECT AS VITAL DIAGNOSTIC TOOLS

The global burden for chronic diseases is increasing worldwide at an alarming rate. To control this situation, the global healthcare industry focuses on early diagnosis of disease to provide prompt treatment. This will facilitate reducing the global burden of chronic diseases such as cardiovascular diseases, chronic obstructive pulmonary disorder, cancer, and others. Diagnostics tools such as PET and SPECT are adopted globally to reduce the rapidly increasing chronic diseases, which provide high-resolution quality imaging, simplifying the complex diagnosis process. This equipment uses PET radiopharmaceuticals with short lifetime radioactive isotopes that are manufactured using fully automated radiosynthesis process. The radiopharmaceuticals are incorporated in the PET/CT/SPECT scanners to improve the utility of tomographic imaging diagnostics methods that are available commercially.

HIGH COST IS A BARRIER FOR ADOPTION OF AUTOMATED RADIOSYNTHESIS MODULE

The manual radiosynthesis module causes exposure to radiation, which can pose as a possible harm to the radiopharmacist. Thus, the new era nuclear medicines and manufacturers of radiolabeled compounds are keen on adoption of automated radiosynthesis module. The average cost of automated radiosynthesis module is more than $50,000. Although these modules provide high accuracy, the high cost of installation and servicing limits its growth in the commercial market. In spite of the fact that there has been a global mandate to use automated radiosynthesis module to reduce radiation exposure to the operator in the clinical setting, the cost pose to be a barrier. The high start-up cost is projected to prohibit the users from the adoption of automated radiosynthesis module, which will further limit the growth of the market at a global platform.

FUNDING AND GRANTS CREATE MARKET OPPORTUNITY WORLDWIDE

The automated radiosynthesis module provides high yield and quality radiopharmaceuticals for multiple applications. Along with high-quality end products, the module also facilitates no radiation exposure to the operator, promoting the adoption of automated synthesis module at a commercial platform. Cost is a major obstacle that may hinder the growth of the global automated radiosynthesis module market. To overcome this constraint and promote the usage of automated radiosynthesis module, there are funding and grands provided by government as well as private institution. For instance, the Department of Energy provided approximately $1 million phase II grant under the Small Business Innovation Research (SBIR) program to develop microscale technology for rapid, simple synthesis of PET probes. These probes are radiopharmaceuticals that are manufactured using automated radiosynthesis module. Moreover, a study was published on May 2015 related to the radiosynthesis of 6-deoxy-6[18F]fluorosucrose using automated synthesis to understand its utility for the study of in vivo sucrose transport in maize (Zea mays) leaves.

The key players that operate in the market include GE Healthcare, Siemens Healthcare, IBA Radiopharma Solutions, Optimized Radiochemical Applications, Synthra GmbH, and Eckert & Ziegler Group.

Other market players in value chain include Sumitomo Corp, Scintomics GmbH, Sofie Biosciences, Trasis S.A, Raytest Isotopenmessgerte GmbH, and Posi-Med LLC.

KEY BENEFITS OF AUTOMATED RADIOSYNTHESIS MODULE MARKET:

  • The study offers a detailed analysis along with market dynamics.
  • A quantitative analysis of the current trends market and future estimations from 2014 to 2020 is provided, enabling all the stakeholders to capitalize the prevailing and emerging opportunities of the market.
  • Key market players and their market share analysis in studied in the report.
  • Strategic analysis of the key leaders and their business strategies within the market are provided, which assist stakeholders to make more informed business decisions.
  • Porters Five Forces analysis examines the competitive structure of the global market and also provides a deeper understanding of the influence factors for market entry and market expansion.

AUTOMATED RADIOSYNTHESIS MODULE MARKET KEY SEGMENTS

By Geography (Value and Volume)

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

The key players that operate in the market include:

  • GE Healthcare
  • Siemens Healthcare
  • IBA Radiopharma Solutions
  • Optimized Radiochemical Applications
  • Synthra GmbH
  • Eckert & Ziegler Group

Other market players in value chain include:

  • Sumitomo Corp
  • Scintomics GmbH
  • Sofie Biosciences
  • Trasis S.A
  • Raytest Isotopenmessgerte GmbH
  • Posi-Med LLC

Table of Contents

Chapter: 1 RESEARCH METHODOLOGY

  • 1.1 Secondary research
  • 1.2 Primary research
  • 1.3 Analyst tools and models

Chapter: 2 MARKET OVERVIEW

  • 2.1 Market definition and scope
  • 2.2 Market dynamics
    • 2.2.1 Drivers
      • 2.2.1.1 Increasing adoption of PET & SPECT as vital diagnostic tools
      • 2.2.1.2 Diverse applications of radiopharmaceuticals in medical industry
    • 2.2.2 Restraints
      • 2.2.2.1 High cost is a barrier for adoption of automated radiosynthesis module
    • 2.2.3 Opportunities
    • 2.2.3.1 Funding and grants create market opportunity worldwide
  • 2.3 Porter's Five Forces Analysis
    • 2.3.1 Bargaining Power of Suppliers
    • 2.3.2 Bargaining Power of Buyers
    • 2.3.3 Threat of New Entrants
    • 2.3.4 Threat of Substitutes
    • 2.3.5 Competitive Rivalry
  • 2.4 Market Share Analysis, 2015

Chapter: 3 WORLD AUTOMATED RADIOSYNTHESIS MODULES MARKET, BY VALUE AND VOLUME

  • 3.1 Market size and forecast

Chapter: 4 WORLD AUTOMATED RADIOSYNTHESIS MODULES MARKET, BY GEOGRAPHY

  • 4.1 North America
    • 4.1.1 Market size and forecast
  • 4.2 Asia-Pacific
    • 4.2.1 Market size and forecast
  • 4.3 Europe
    • 4.3.1 Market size and forecast
  • 4.4 LAMEA
    • 4.4.1 Market size and forecast

Chapter: 5 COMPANY PROFILES

  • 5.1 GE Healthcare
    • 5.1.1 Company Overview
    • 5.1.2 Company Snapshot
    • 5.1.3 Operating Business Segments
    • 5.1.4 Business Performance
    • 5.1.5 Key Strategic Moves and Developments
  • 5.2 Siemens Healthcare
    • 5.2.1 Company Overview
    • 5.2.2 Company Snapshot
    • 5.2.3 Operating Business Segments
    • 5.2.4 Business Performance
    • 5.2.5 Key Strategic Moves and Developments
  • 5.3 IBA Radiopharma Solutions
    • 5.3.1 Company Overview
    • 5.3.2 Company Snapshot
    • 5.3.3 Operating Business Segments
    • 5.3.4 Business Performance
    • 5.3.5 Key Strategic Moves and Developments
  • 5.4 Optimized Radiochemical Applications
    • 5.4.1 Company Overview
    • 5.4.2 Company Snapshot
    • 5.4.3 Operating Business Segments
    • 5.4.4 Business Performance
    • 5.4.5 Key Strategic Moves and Developments
  • 5.5 Synthra GmbH
    • 5.5.1 Company Overview
    • 5.5.2 Company Snapshot
    • 5.5.3 Operating Business Segments
    • 5.5.4 Business Performance
    • 5.5.5 Key Strategic Moves and Developments
  • 5.6 Eckert
    • 5.6.1 Company Overview
    • 5.6.2 Company Snapshot
    • 5.6.3 Operating Business Segments
    • 5.6.4 Business Performance
    • 5.6.5 Key Strategic Moves and Developments
  • 5.7 Ziegler Group
    • 5.7.1 Company Overview
    • 5.7.2 Company Snapshot
    • 5.7.3 Operating Business Segments
    • 5.7.4 Business Performance
    • 5.7.5 Key Strategic Moves and Developments

List of Figures

  • FIG. 1 TOP FACTORS IMPACTING GLOBAL ENERGY STORAGE SYSTEMS MARKET
  • FIG. 2 NUMBER OF INSTALLATION OF PET SCANNER WORLDWIDE IN 2014
  • FIG. 3 NUMBER OF INSTALLATION OF PET SCANNER WORLDWIDE IN 2015
  • FIG. 4 ESTIMATED NEW CASES OF CANCER WORLDWIDE IN MALE IN 2012
  • FIG. 5 ESTIMATED NEW CASES OF CANCER WORLDWIDE IN MALE IN 2012
  • FIG. 6 GLOBAL ESTIMATED AVAILABILITY OF RADIOTHERAPY, 2013
  • FIG. 7 PORTER'S FIVE FORCES ANALYSIS
  • FIG. 8 MARKET SHARE ANALYSIS, 2015 (% SHARE)

List of Tables

  • TABLE 1 GLOBAL STATISTICS FOR CHRONIC DISEASES
  • TABLE 2 FDA-RECOGNIZED RADIOPHARMACEUTICALS FOR PET
  • TABLE 3 WORLD AUTOMATED RADIOSYNTHESIS MODULES MARKET, 2014-2022 (NUMBER OF UNITS) ($ MILLION)
  • TABLE 4 NORTH AMERICA AUTOMATED RADIOSYNTHESIS MODULES MARKET, 2014-2022 (NUMBER OF UNITS) ($ MILLION)
  • TABLE 5 ASIA-PACIFIC AUTOMATED RADIOSYNTHESIS MODULES MARKET, 2014-2022 (NUMBER OF UNITS) ($ MILLION)
  • TABLE 6 EUROPE AUTOMATED RADIOSYNTHESIS MODULES MARKET, 2014-2022 (NUMBER OF UNITS) ($ MILLION)
  • TABLE 7 LAMEA AUTOMATED RADIOSYNTHESIS MODULES MARKET, 2014-2022 (NUMBER OF UNITS) ($ MILLION)
  • TABLE 8 GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 9 GE HEALTHCARE: OPERATING SEGMENTS
  • TABLE 10 SIEMENS HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 11 SIEMENS HEALTHCARE: OPERATING SEGMENTS
  • TABLE 12 IBA RADIOPHRAMA: COMPANY SNAPSHOT
  • TABLE 13 IBA RADIOPHARMA: OPERATING SEGMENTS
  • TABLE 14 OPTIMIZED RADIOCHEMICAL: COMPANY SNAPSHOT
  • TABLE 15 OPTIMIZED READIOCHEMICAL: OPERATING SEGMENTS
  • TABLE 16 SYNTHRA: COMPANY SNAPSHOT
  • TABLE 17 SYNTHRA: OPERATING SEGMENTS
  • TABLE 18 ECKERT: COMPANY SNAPSHOT
  • TABLE 19 ECKERT: OPERATING SEGMENTS
  • TABLE 20 ZIEGLER: COMPANY SNAPSHOT
  • TABLE 21 ZIEGLER: OPERATING SEGMENTS

List of Tables

  • TABLE 1 WORLD INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 2 WORLD ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 3 ANGIOPLASTY BALLOONS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 4 WORLD ANGIOPLASTY STENTS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 5 WORLD CORONARY STENTS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 6 ANGIOPLASTY STENTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 7 WORLD ANGIOPLASTY CATHETERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 8 ANGIOPLASTY CATHETERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 9 WORLD ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 10 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11 TYPES OF IVC FILTERS AVAILABLE IN THE MARKET
  • TABLE 12 WORLD INFERIOR VENA CAVA (IVC) FILTERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 13 INFERIOR VENA CAVA (IVC) FILTERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 14 WORLD PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 15 PLAQUE MODIFICATION DEVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 16 WORLD HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 17 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 18 WORLD ACCESSORIES MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 19 ACCESSORIES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 20 INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 21 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 22 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 23 EUROPE: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 24 EUROPE: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 25 ASIA-PACIFIC: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 26 ASIA-PACIFIC: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 27 LAMEA: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 28 LAMEA: INTERVENTIONAL CARDIOLOGY & PERIPHERAL VASCULAR DEVICES MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 29 ABBOTT: COMPANY SNAPSHOT
  • TABLE 30 ABBOTT: OPERATING SEGMENTS
  • TABLE 31 B. BRAUN: COMPANY SNAPSHOT
  • TABLE 32 B. BRAUN: OPERATING SEGMENTS
  • TABLE 33 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 34 BOSTON SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 35 BARD: COMPANY SNAPSHOT
  • TABLE 36 BARD: OPERATING SEGMENTS
  • TABLE 37 CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 38 CARDINAL HEALTH: OPERATING SEGMENTS
  • TABLE 39 COOK MEDICAL: COMPANY SNAPSHOT
  • TABLE 40 COOK MEDICAL: DIVISIONS
  • TABLE 41 MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 42 MEDTRONIC: OPERATING SEGMENTS
  • TABLE 43 ST. JUDE MEDICAL: COMPANY SNAPSHOT
  • TABLE 44 ST. JUDE MEDICAL: PRODUCT CATEGORIES
  • TABLE 45 TERUMO: COMPANY SNAPSHOT
  • TABLE 46 TERUMO: OPERATING SEGMENTS
  • TABLE 47 SPECTRANETICS: COMPANY SNAPSHOT
  • TABLE 48 SPECTRANETICS: OPERATING SEGMENTS
Back to Top